Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 102,979 shares, a decline of 33.9% from the September 30th total of 155,699 shares. Based on an average trading volume of 263,817 shares, the short-interest ratio is currently 0.4 days.
Tevogen Bio Stock Up 11.0%
TVGNW traded up $0.01 during midday trading on Tuesday, reaching $0.09. The company had a trading volume of 361,366 shares, compared to its average volume of 247,015. Tevogen Bio has a 12-month low of $0.03 and a 12-month high of $0.12. The business has a 50-day moving average price of $0.06 and a two-hundred day moving average price of $0.05.
Tevogen Bio Company Profile
Tevogen Bio is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and other immune-related diseases. The company’s platform is designed to produce targeted, off-the-shelf therapies using virus-specific cytotoxic T lymphocytes, with the aim of providing treatment without the need to collect and modify each patient’s own cells.
Tevogen’s lead product candidate, TVGN 489, is an investigational allogeneic T-cell therapy intended to target SARS-CoV-2-infected cells.
Further Reading
- Five stocks we like better than Tevogen Bio
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
